We are live on ! Find out more
RXDX

Prometheus Biosciences, Inc. Common Stock
RXDX

Delisted

RXDX was delisted on the 15th of June, 2023.

Back to rankings

2 hedge funds and large institutions have $1.98M invested in Prometheus Biosciences, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 216 closing their positions.

New
Increased
Maintained
Reduced
Closed

74% less call options, than puts

Call options by funds: $13.6M | Put options by funds: $51.5M

99% less funds holding

Funds holding: 219 → 2 (-217)

100% less capital invested

Capital invested by funds: $4.35B → $1.98M (-$4.35B)

100% less funds holding in top 10

Funds holding in top 10: 13 → 0 (-13)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 216

Holders
2
Holders Change
-217
Holders Change %
-99.09%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-13
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
216
Calls
$13.6M
Puts
$51.5M
Net Calls
-$37.9M
Net Calls Change
-$118M

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$351M
2
BlackRock
BlackRock
New York
-$300M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$292M
4
BC
Boxer Capital
California
-$204M
5
7IH
72 Investment Holdings
Connecticut
-$198M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
– -$41.9M -390,276 Closed
Bank of America
27
Bank of America
North Carolina
– -$40.6M -378,016 Closed
Deutsche Bank
28
Deutsche Bank
Germany
– -$38.8M -361,534 Closed
Invesco
29
Invesco
Georgia
– -$38.6M -359,749 Closed
Millennium Management
30
Millennium Management
New York
– -$35.6M -331,258 Closed
Northern Trust
31
Northern Trust
Illinois
– -$34.1M -317,526 Closed
WP
32
Woodline Partners
California
– -$34M -317,113 Closed
Franklin Resources
33
Franklin Resources
California
– -$29.4M -273,810 Closed
NIP
34
Nicholas Investment Partners
California
– -$29.3M -272,910 Closed
DCM
35
Driehaus Capital Management
Illinois
– -$28.7M -267,399 Closed
Charles Schwab
36
Charles Schwab
California
– -$27.5M -255,928 Closed
PAMS
37
Pictet Asset Management (Switzerland)
Switzerland
– -$27M -251,806 Closed
Renaissance Technologies
38
Renaissance Technologies
New York
– -$26.2M -243,875 Closed
PIM
39
Platinum Investment Management
Australia
– -$24.8M -231,521 Closed
N
40
Nuveen
North Carolina
– -$23.9M -222,679 Closed
Capital World Investors
41
Capital World Investors
California
– -$22M -205,400 Closed
Goldman Sachs
42
Goldman Sachs
New York
– -$22M -204,858 Closed
LCM
43
Laurion Capital Management
New York
– -$21M -195,663 Closed
Voloridge Investment Management
44
Voloridge Investment Management
Florida
– -$19.2M -179,285 Closed
Ensign Peak Advisors
45
Ensign Peak Advisors
Utah
– -$19M -177,457 Closed
Victory Capital Management
46
Victory Capital Management
Texas
– -$18.6M -172,914 Closed
Principal Financial Group
47
Principal Financial Group
Iowa
– -$18M -167,475 Closed
TCM
48
TimesSquare Capital Management
New York
– -$17.6M -164,055 Closed
WCA
49
Waypoint Capital Advisors
Minnesota
– -$16.6M -154,466 Closed
Norges Bank
50
Norges Bank
Norway
– -$16.5M -153,492 Closed
1
2
3 4 5

RXDX Hedge Fund Activity: Q2 2023 in Review

2 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q2 2023, worth a combined $1.98M — down 100% from $4.35B a quarter earlier.

Sellers outnumbered buyers: 216 funds closed out of RXDX and 0 opened new positions — a net loss of 216 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was RTW Investments, exiting entirely with an estimated $351M sold.

  • 2 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q2 2023, down from 219 in Q1 2023.
  • Funds reported $1.98M of Prometheus Biosciences, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q2 2023 and 216 closed out, a net change of -216 holders.
  • The largest Prometheus Biosciences, Inc. Common Stock seller in Q2 2023 was RTW Investments, an estimated $351M sold.

Based on aggregated 13F filings for Q2 2023.